These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21505426)

  • 1. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.
    King GD; Muhammad AK; Larocque D; Kelson KR; Xiong W; Liu C; Sanderson NS; Kroeger KM; Castro MG; Lowenstein PR
    Mol Ther; 2011 Oct; 19(10):1793-801. PubMed ID: 21505426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.
    King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AK; Pechnick RN; Lowenstein PR; Castro MG
    Mol Ther; 2008 Apr; 16(4):682-90. PubMed ID: 18283279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.
    Candolfi M; King GD; Yagiz K; Curtin JF; Mineharu Y; Muhammad AK; Foulad D; Kroeger KM; Barnett N; Josien R; Lowenstein PR; Castro MG
    Neoplasia; 2012 Aug; 14(8):757-70. PubMed ID: 22952428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
    Ghulam Muhammad AK; Candolfi M; King GD; Yagiz K; Foulad D; Mineharu Y; Kroeger KM; Treuer KA; Nichols WS; Sanderson NS; Yang J; Khayznikov M; Van Rooijen N; Lowenstein PR; Castro MG
    Clin Cancer Res; 2009 Oct; 15(19):6113-27. PubMed ID: 19789315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.
    Puntel M; Muhammad AK; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Bondale NS; Lerner J; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
    J Virol; 2010 Jun; 84(12):6007-17. PubMed ID: 20375153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
    Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
    Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
    King GD; Muhammad AK; Curtin JF; Barcia C; Puntel M; Liu C; Honig SB; Candolfi M; Mondkar S; Lowenstein PR; Castro MG
    Neuro Oncol; 2008 Feb; 10(1):19-31. PubMed ID: 18079358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMGB1 mediates endogenous TLR2 activation and brain tumor regression.
    Curtin JF; Liu N; Candolfi M; Xiong W; Assi H; Yagiz K; Edwards MR; Michelsen KS; Kroeger KM; Liu C; Muhammad AK; Clark MC; Arditi M; Comin-Anduix B; Ribas A; Lowenstein PR; Castro MG
    PLoS Med; 2009 Jan; 6(1):e10. PubMed ID: 19143470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
    Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
    Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
    Candolfi M; Yagiz K; Foulad D; Alzadeh GE; Tesarfreund M; Muhammad AK; Puntel M; Kroeger KM; Liu C; Lee S; Curtin JF; King GD; Lerner J; Sato K; Mineharu Y; Xiong W; Lowenstein PR; Castro MG
    Clin Cancer Res; 2009 Jul; 15(13):4401-14. PubMed ID: 19570774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.
    Candolfi M; Curtin JF; Yagiz K; Assi H; Wibowo MK; Alzadeh GE; Foulad D; Muhammad AK; Salehi S; Keech N; Puntel M; Liu C; Sanderson NR; Kroeger KM; Dunn R; Martins G; Lowenstein PR; Castro MG
    Neoplasia; 2011 Oct; 13(10):947-60. PubMed ID: 22028620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.
    VanderVeen N; Raja N; Yi E; Appelman H; Ng P; Palmer D; Zamler D; Dzaman M; Lowenstein PR; Castro MG
    Hum Gene Ther Methods; 2016 Jun; 27(3):98-111. PubMed ID: 27056322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.
    Muhammad AK; Puntel M; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Lawrence K; Bondale NS; Lerner J; Baker GJ; Foulad D; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
    Clin Pharmacol Ther; 2010 Aug; 88(2):204-13. PubMed ID: 20164833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
    Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
    PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.
    VanderVeen N; Paran C; Krasinkiewicz J; Zhao L; Palmer D; Hervey-Jumper S; Ng P; Lowenstein PR; Castro MG
    Hum Gene Ther Clin Dev; 2013 Sep; 24(3):116-26. PubMed ID: 24007469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
    Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
    Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models.
    Alghamri MS; Núñez FJ; Kamran N; Carney S; Altshuler D; Lowenstein PR; Castro MG
    Methods Enzymol; 2020; 631():91-106. PubMed ID: 31948569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for brain tumors: basic developments and clinical implementation.
    Assi H; Candolfi M; Baker G; Mineharu Y; Lowenstein PR; Castro MG
    Neurosci Lett; 2012 Oct; 527(2):71-7. PubMed ID: 22906921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral Deficits.
    King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AG; Pechnick RN; Lowenstein PR; Castro MG
    Mol Ther; 2008 Apr; 16(4):682-690. PubMed ID: 28178463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.